PRESS CLIPPING SHEET

PUBLICATION:	**Daily News**
DATE:	**15-February-2018**
COUNTRY:	**Egypt**
CIRCULATION:	**80,000**
TITLE :	**Novartis Worldwide presents evidence for Secukinumab on potential to maintain mobility in patients with AS, PsA**
PAGE:	**06**
ARTICLE TYPE:	**Agency-Generated News**
REPORTER:	**Staff Report**
AVE:	**8,060**



Novartis Worldwide presents evidence for Secukinumab on potential to maintain mobility in patients with AS, PsA

New evidence on the efficacy of the innovative biologic Secukinumab, demonstrating its potential to reduce structural disease progression in patients with specific rheumatological conditions, was presented at the 2017 ACR/ARHP Annual Meeting in San Diego, United States. The late-breaking Secukinumab presentations included new four-year data from the MEASURE 1 study in patients with ankylosing spondylitis (AS), and 24-week data from the FUTURE 5 study in patients with psoriatic arthritis (PsA), two debilitating autoimmune diseases with a high risk of mobility loss.

"Maintaining mobility is our hope and vision for every patient with chronic inflammatory diseases such as AS and PsA," said Vas Narasimhan, CEO of Novartis. "Reducing radiographic progression would be a strong signal for patients who hope to stay mobile, as this would result in a significant improvement of their quality of life."

Secukinumab is a fully human-targeted biologic approved for patients with AS, PsA, or psoriasis (PsO). Secukinumab is the first and only fully human monoclonal antibody that selectively neutralises interleukin-17A (IL-17A), the key cytokine involved in the pathogenesis of AS, PsA, and PsO. Today, Secukinumab has been used by more than 100,000 patients worldwide. Across all three indications, Secukinumab has demonstrated rapid and sustained efficacy as well as a consistently favourable safety profile, including close to zero injection site reactions or associated pain.